Date of report 16 Apr 2024
Reported case interaction between
Cobicistat and APIXABAN
Cobicistat and APIXABAN
Drugs suspected to be involved in the DDI
Complete list of drugs taken by the patient
Olanzapine, apixaban (2.5 mg 2x/day)
Clinical case description
A 74-year-old patient, well controlled on treatment with Elvitegravir/cobi/FTC/TAF, was started on apixaban at a reduced dose (2.5 mg twice daily) for thrombosis in the left leg. The concurrent use of apixaban at a reduced dose was well tolerated with no adverse outcomes. Apixaban is metabolized by CYP3A4 and, to a lesser extent, by CYP1A2, 2C8, 2C9, 2C19 and 2J2. Additionally, apixaban is a substrate of P-gp and BCRP. Elvitegravir/cobicistat inhibits CYP3A4, P-gp and BRCP and therefore increases the exposure of apixaban. The product label for apixaban does not recommend the concomitant use with strong dual CYP3A4 and P-gp inhibitors, although the US label gives the option to use apixaban at a reduced dose (i.e., 2.5 mg) if needed. Of interest, the literature reports case series of people with HIV treated with a reduced dose of apixaban (2.5 mg twice daily) while on ritonavir or cobicistat boosted regimens, which did not present adverse outcomes.
Clinical Outcome
Editorial Comment
Concentrations of apixaban are expected to increase due to potent CYP3A4 and P-gp inhibition by elvitegravir/cobicistat, thereby increasing the bleeding risk.
This clinical case highlights the safety of an interaction that is becoming increasingly common, that of boosters with the new oral anticoagulants. This patient was started on the adjusted dose of apixaban and received elvitegravir/cobi/FTC/TAF plus half-dose of apixaban for several weeks (at least 2 months) without any adverse outcome.
University of Liverpool Recommendation
Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration